semaglutide oral cardiovascular indication news 2025 semaglutide oral cardiovascular indication 2025 news At ADA 2025, the SOUL trial revealed that oral semaglutide ( Oral Semaglutide and Cardiovascular Outcomes

Attorneys for defendants Novo Nordisk and Eli Lilly filed their notices of appearance and more plaintiffs continue to transfer into the MDL

147 Additionally, by incorporating advanced hydrogel-based delivery systems, the targeted administration of therapeutic agents such as growth factors and small RNAs can be optimized to minimize off-target effects while maximizing cardiac functional recovery

Modern frameworks make this possible by supporting secure data handling, real-time interactions, and consistent user experiences across platforms

It is especially beneficial for patients with a BMI of 30 or greater who need significant weight reduction alongside diabetes management